<p>MediciNova, Inc.（纳斯达克代码：MNOV - 获取免费报告）在周一的交易中，股价突破了其 200 日移动平均线。该股票的 200 日移动平均线为 1.33 美元，最高交易价为 1.4570 美元。MediciNova 的股票最后交易价为 1.41 美元，成交量为 52,520 股。</p>
<h2>分析师评级调整</h2>
<p>MNOV 已成为多份分析师报告的主题。D. Boral Capital 在 10 月 31 日的研究报告中重申了对 MediciNova 的 “买入” 评级，并给出了 9.00 美元的目标价。Weiss Ratings 在 11 月 24 日的研究报告中重申了对 MediciNova 的 “卖出（d-）” 评级。最后，Zacks Research 在 9 月 11 日的研究报告中将 MediciNova 的评级上调至 “持有”。一位股票研究分析师给予该股票 “强烈买入” 评级，一位给予 “买入” 评级，一位给予 “持有” 评级，另一位给予 “卖出” 评级。根据 MarketBeat 的数据，MediciNova 目前的共识评级为 “适度买入”，共识目标价为 7.00 美元。</p>
<p><strong>查看我们对 MediciNova 的最新股票分析</strong></p>
<h2>MediciNova 价格表现</h2>
<p>该股票的市值为 6916 万美元，市盈率为-5.64，贝塔系数为 0.50。该股票的 50 日移动平均线为 1.34 美元，200 日移动平均线为 1.33 美元。</p>
<p>MediciNova（纳斯达克代码：MNOV - 获取免费报告）最近在 11 月 12 日发布了其财报。这家生物制药公司报告本季度每股收益（EPS）为-0.06 美元，超出分析师共识预期的-0.08 美元，超出幅度为 0.02 美元。该公司本季度的收入为 12 万美元。分析师预计 MediciNova, Inc.在本年度将发布-0.24 的每股收益。</p>
<h2>机构投资者对 MediciNova 的看法</h2>
<p>一家机构投资者最近在 MediciNova 股票中购买了新头寸。根据该公司最近向证券交易委员会（SEC）提交的文件，Citadel Advisors LLC 在第三季度收购了 MediciNova, Inc.（纳斯达克代码：MNOV - 免费报告）的新股份。该公司收购了 72,897 股生物制药公司的股票，价值约 92,000 美元。根据其最近的 SEC 文件，Citadel Advisors LLC 持有 MediciNova 的 0.15%。对冲基金和其他机构投资者持有该公司 9.90% 的股票。</p>
<h2>关于 MediciNova</h2>
<p>（获取免费报告）</p>
<p>MediciNova, Inc.是一家生物制药公司，专注于开发新型小分子治疗药物，以治疗美国未满足医疗需求的严重疾病。它正在开发 MN-166（伊布利斯特），这是一种口服抗炎和神经保护剂，用于治疗神经系统及其他疾病，如原发性和继发性进展性多发性硬化症、肌萎缩侧索硬化症、化疗引起的周围神经病、退行性颈髓病、胶质母细胞瘤以及物质依赖和成瘾，以及预防急性呼吸窘迫综合症和长期新冠。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们更看好的股票，胜过 MediciNova</li>
<li>如何捕捉股息增长的好处</li>
<li>预计 2025 年上涨超过 20%，这三只股票正在提升回购能力</li>
<li>Roth IRA 计算器：计算您的潜在回报</li>
<li>国会再次超越市场——以下是他们购买的三只股票</li>
<li>如何投资小盘股</li>
<li>与三只顶级零售 ETF 一起购物</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资 1,000 美元在 MediciNova 吗？</h2>
<p>在您考虑 MediciNova 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 MediciNova 并不在名单上。</p>
<p>虽然 MediciNova 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

美第奇新星生物技术

<p>美第奇新星生物技术（NASDAQ:MNOV）的股票最近突破了其 200 日移动平均线，交易价格最高达到 1.4570 美元。分析师的评级各不相同：D. Boral Capital 给予 “买入” 评级，目标价为 9.00 美元，Weiss Ratings 则建议 “卖出（d-）”，而 Zacks Research 将其评级上调至 “持有”。该股票的市值为 6916 万美元，市盈率为-5.64。包括 Citadel Advisors LLC 在内的机构投资者对其表现出兴趣，持有 9.90% 的股份。美第奇新星生物技术专注于开发满足未满足需求的严重疾病治疗方案</p>

<p>MediciNova, Inc. (NASDAQ:MNOV - Get Free Report)'s stock price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.33 and traded as high as $1.4570. MediciNova shares last traded at $1.41, with a volume of 52,520 shares changing hands.</p>
<div class="lb-trans"><p>MediciNova, Inc.（纳斯达克代码：MNOV - 获取免费报告）在周一的交易中，股价突破了其 200 日移动平均线。该股票的 200 日移动平均线为 1.33 美元，最高交易价为 1.4570 美元。MediciNova 的股票最后交易价为 1.41 美元，成交量为 52,520 股。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级调整</h2>
</div><p>MNOV has been the topic of a number of analyst reports. D. Boral Capital restated a &#34;buy&#34; rating and issued a $9.00 price target on shares of MediciNova in a research note on Friday, October 31st. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of MediciNova in a research note on Monday, November 24th. Finally, Zacks Research upgraded MediciNova to a &#34;hold&#34; rating in a research report on Thursday, September 11th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, MediciNova currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $7.00.</p>
<div class="lb-trans"><p>MNOV 已成为多份分析师报告的主题。D. Boral Capital 在 10 月 31 日的研究报告中重申了对 MediciNova 的 “买入” 评级，并给出了 9.00 美元的目标价。Weiss Ratings 在 11 月 24 日的研究报告中重申了对 MediciNova 的 “卖出（d-）” 评级。最后，Zacks Research 在 9 月 11 日的研究报告中将 MediciNova 的评级上调至 “持有”。一位股票研究分析师给予该股票 “强烈买入” 评级，一位给予 “买入” 评级，一位给予 “持有” 评级，另一位给予 “卖出” 评级。根据 MarketBeat 的数据，MediciNova 目前的共识评级为 “适度买入”，共识目标价为 7.00 美元。</p>
</div><p><strong>View Our Latest Stock Analysis on MediciNova</strong></p>
<div class="lb-trans"><p><strong>查看我们对 MediciNova 的最新股票分析</strong></p>
</div><h2>MediciNova Price Performance</h2>
<div class="lb-trans"><h2>MediciNova 价格表现</h2>
</div><p>The stock has a market cap of $69.16 million, a price-to-earnings ratio of -5.64 and a beta of 0.50. The stock's 50-day moving average is $1.34 and its 200 day moving average is $1.33.</p>
<div class="lb-trans"><p>该股票的市值为 6916 万美元，市盈率为-5.64，贝塔系数为 0.50。该股票的 50 日移动平均线为 1.34 美元，200 日移动平均线为 1.33 美元。</p>
</div><p>MediciNova (NASDAQ:MNOV - Get Free Report) last issued its earnings results on Wednesday, November 12th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.08) by $0.02. The business had revenue of $0.12 million for the quarter. Analysts anticipate that MediciNova, Inc. will post -0.24 EPS for the current year.</p>
<div class="lb-trans"><p>MediciNova（纳斯达克代码：MNOV - 获取免费报告）最近在 11 月 12 日发布了其财报。这家生物制药公司报告本季度每股收益（EPS）为-0.06 美元，超出分析师共识预期的-0.08 美元，超出幅度为 0.02 美元。该公司本季度的收入为 12 万美元。分析师预计 MediciNova, Inc.在本年度将发布-0.24 的每股收益。</p>
</div><h2>Institutional Investors Weigh In On MediciNova</h2>
<div class="lb-trans"><h2>机构投资者对 MediciNova 的看法</h2>
</div><p>An institutional investor recently bought a new position in MediciNova stock. Citadel Advisors LLC acquired a new stake in MediciNova, Inc. (NASDAQ:MNOV - Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 72,897 shares of the biopharmaceutical company's stock, valued at approximately $92,000. Citadel Advisors LLC owned 0.15% of MediciNova as of its most recent SEC filing. Hedge funds and other institutional investors own 9.90% of the company's stock.</p>
<div class="lb-trans"><p>一家机构投资者最近在 MediciNova 股票中购买了新头寸。根据该公司最近向证券交易委员会（SEC）提交的文件，Citadel Advisors LLC 在第三季度收购了 MediciNova, Inc.（纳斯达克代码：MNOV - 免费报告）的新股份。该公司收购了 72,897 股生物制药公司的股票，价值约 92,000 美元。根据其最近的 SEC 文件，Citadel Advisors LLC 持有 MediciNova 的 0.15%。对冲基金和其他机构投资者持有该公司 9.90% 的股票。</p>
</div><h2>About MediciNova</h2>
<div class="lb-trans"><h2>关于 MediciNova</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.</p>
<div class="lb-trans"><p>MediciNova, Inc.是一家生物制药公司，专注于开发新型小分子治疗药物，以治疗美国未满足医疗需求的严重疾病。它正在开发 MN-166（伊布利斯特），这是一种口服抗炎和神经保护剂，用于治疗神经系统及其他疾病，如原发性和继发性进展性多发性硬化症、肌萎缩侧索硬化症、化疗引起的周围神经病、退行性颈髓病、胶质母细胞瘤以及物质依赖和成瘾，以及预防急性呼吸窘迫综合症和长期新冠。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than MediciNova</li>
<li>How to Capture the Benefits of Dividend Increases</li>
<li>Up Over 20% in 2025, These 3 Stocks Are Boosting Buyback Capacity</li>
<li>Roth IRA Calculator: Calculate Your Potential Returns</li>
<li>Congress Beat the Market Again—Here Are the 3 Stocks They Bought</li>
<li>How to Invest in Small Cap Stocks</li>
<li>Go on a Shopping Spree With 3 Top Retail ETFs</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 MediciNova</li>
<li>如何捕捉股息增长的好处</li>
<li>预计 2025 年上涨超过 20%，这三只股票正在提升回购能力</li>
<li>Roth IRA 计算器：计算您的潜在回报</li>
<li>国会再次超越市场——以下是他们购买的三只股票</li>
<li>如何投资小盘股</li>
<li>与三只顶级零售 ETF 一起购物</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in MediciNova Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1,000 美元在 MediciNova 吗？</h2>
</div><p>Before you consider MediciNova, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑 MediciNova 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MediciNova wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 MediciNova 并不在名单上。</p>
</div><p>While MediciNova currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 MediciNova 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

美第奇新星生物技术（NASDAQ:MNOV）股票突破 200 日移动平均线 - 你是否应该卖出？